Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

SANZ Risk Score (APL)

The Sanz Risk Score (PETHEMA/GIMEMA) stratifies APL patients to guide treatment intensity.

Evidence-based context for fast calculator use

Purpose:
Sanz Risk Score stratifies APL patients by WBC and platelet count to guide ATRA-based treatment intensity in Acute Promyelocytic Leukemia.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
WBC Count, Platelet Count
Reference:
Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247-1253.
HomeSANZ Risk Score (APL)
Pin your most used calculators here by clicking the star in the dropdown.

SANZ Risk Score (APL)

x10⁹/L
x10⁹/L

Clinical Context & Background

The Sanz Risk Score (PETHEMA/GIMEMA) stratifies APL patients to guide treatment intensity. It is particularly crucial for determining whether patients should receive ATRA + Arsenic Trioxide (ATO) (Low/Intermediate Risk) or Cytotoxic Chemotherapy (High Risk).
Primary Source EvidenceSanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247-1253.
Formula Logic
Based on WBC and Platelet count.

Reference Data

Risk GroupCriteriaStandard of Care
Low RiskWBC ≤ 10 and Platelets > 40ATRA + ATO (Chemo-free)
IntermediateWBC ≤ 10 and Platelets ≤ 40ATRA + ATO (Chemo-free)
High RiskWBC > 10ATRA + Chemo (or ATRA+ATO+Gemtuzumab)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use SANZ Risk Score (APL) when sanz Risk Score stratifies APL patients by WBC and platelet count to guide ATRA-based treatment intensity in Acute Promyelocytic Leukemia.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify WBC Count, Platelet Count, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should SANZ Risk Score (APL) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can SANZ Risk Score (APL) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.